Survivor costs in cost-effectiveness analysis.
Gandjour
Afschin
A
D000935:Antifungal Agents / Q000191:economics* / Q000627:therapeutic use*; D002177:Candidiasis / Q000188:drug therapy*; D003362:Cost-Benefit Analysis; D003428:Cross Infection / Q000188:drug therapy*; D003627:Data Interpretation, Statistical; D006801:Humans; D016019:Survival Analysis
D000935:Antifungal Agents